Hypomethylating Agents (HMAs) as Salvage Therapy in Relapsed or Refractory AML: An Italian Multicentric Retrospective Study.
HMA
acute myeloid leukemia
azacytidine
decitabine
refractory
relapsed
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
06 Aug 2021
06 Aug 2021
Historique:
received:
31
05
2021
revised:
30
07
2021
accepted:
02
08
2021
entrez:
27
8
2021
pubmed:
28
8
2021
medline:
28
8
2021
Statut:
epublish
Résumé
Data on the use of azacytidine and decitabine as salvage therapy for acute myeloid leukemia are limited. We retrospectively reviewed clinical records of 100 patients treated with hypomethylating agents (HMA) as salvage therapy in nine Italian institutions. A total of 24% of patients obtained a response to HMA (CR, PR, or CRi), while 26% showed a stable disease (SD); 50% of patients experienced progressive disease. Median OS was 6.5 months. OS in patients with de novo AML was 6.1 months, while OS in patients with secondary AML (sAML) was 12.3 months (
Identifiants
pubmed: 34440176
pii: biomedicines9080972
doi: 10.3390/biomedicines9080972
pmc: PMC8394759
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Am Soc Clin Oncol Educ Book. 2019 Jan;39:421-432
pubmed: 31099627
Best Pract Res Clin Haematol. 2018 Dec;31(4):384-386
pubmed: 30466752
Leuk Res. 2015 Feb;39(2):124-30
pubmed: 25524177
Am J Hematol. 2013 Jul;88(7):601-5
pubmed: 23619977
Int J Hematol. 2018 Feb;107(2):138-150
pubmed: 29143282
Am J Hematol. 2018 Jun 15;:
pubmed: 29905379
Lancet Haematol. 2016 May;3(5):e212-3
pubmed: 27132694
Blood Rev. 2017 Mar;31(2):43-62
pubmed: 27745715
Blood Adv. 2018 Apr 24;2(8):923-932
pubmed: 29685952
Blood. 2015 Jul 16;126(3):291-9
pubmed: 25987659
Haematologica. 2016 Jul;101(7):879-83
pubmed: 27081178
Am J Hematol. 2014 Apr;89(4):410-6
pubmed: 24375487
J Clin Oncol. 2012 Jul 20;30(21):2670-7
pubmed: 22689805
Am J Hematol. 2018 Mar;93(3):401-407
pubmed: 29218851
Cancers (Basel). 2020 Jan 02;12(1):
pubmed: 31906489
Leuk Res. 2019 Jan;76:33-38
pubmed: 30529681
Cancers (Basel). 2019 Feb 14;11(2):
pubmed: 30769877
Leuk Lymphoma. 2013 Sep;54(9):2003-7
pubmed: 23270581
Cancer. 2012 Feb 15;118(4):1014-22
pubmed: 21761399
Clin Lymphoma Myeloma Leuk. 2020 Feb;20(2):e66-e75
pubmed: 31862181
Leuk Res. 2020 Mar;90:106314
pubmed: 32035355
Blood. 2012 Apr 5;119(14):3361-9
pubmed: 22234690
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058